Limits...
A reliable Raman-spectroscopy-based approach for diagnosis, classification and follow-up of B-cell acute lymphoblastic leukemia.

Managò S, Valente C, Mirabelli P, Circolo D, Basile F, Corda D, De Luca AC - Sci Rep (2016)

Bottom Line: B-ALL diagnosis requires identification and classification of the leukemia cells.In combination with immunofluorescence and Western blotting, we show that these Raman markers reflect the relative changes in the potential biological markers from cell surface antigens, cytoplasmic proteins, and DNA content and correlate with the lymphoblastic B-cell maturation/differentiation stages.Our study demonstrates the potential of this technique for classification of B-leukemia cells into the different differentiation/maturation stages, as well as for the identification of key biochemical changes under chemotherapeutic treatments.

View Article: PubMed Central - PubMed

Affiliation: Institute of Protein Biochemistry, National Research Council, Via P. Castellino 111, 80131 Naples, Italy.

ABSTRACT
Acute lymphoblastic leukemia type B (B-ALL) is a neoplastic disorder that shows high mortality rates due to immature lymphocyte B-cell proliferation. B-ALL diagnosis requires identification and classification of the leukemia cells. Here, we demonstrate the use of Raman spectroscopy to discriminate normal lymphocytic B-cells from three different B-leukemia transformed cell lines (i.e., RS4;11, REH, MN60 cells) based on their biochemical features. In combination with immunofluorescence and Western blotting, we show that these Raman markers reflect the relative changes in the potential biological markers from cell surface antigens, cytoplasmic proteins, and DNA content and correlate with the lymphoblastic B-cell maturation/differentiation stages. Our study demonstrates the potential of this technique for classification of B-leukemia cells into the different differentiation/maturation stages, as well as for the identification of key biochemical changes under chemotherapeutic treatments. Finally, preliminary results from clinical samples indicate high consistency of, and potential applications for, this Raman spectroscopy approach.

No MeSH data available.


Related in: MedlinePlus

Differentiation scheme and morphology of the RS4;11, REH and MN60 B-leukemia cell lines.(a) Immunophenotypic profile with the coordinate and sequential well-characterized plasma-membrane antigen expression. (b) Morphologic features and immunophenotypic expression pattern. (c) Representative images of the cell morphology using May Grunwald-Giemsa histochemical staining for DNA and RNA molecules. Scale bar: 10 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4835730&req=5

f1: Differentiation scheme and morphology of the RS4;11, REH and MN60 B-leukemia cell lines.(a) Immunophenotypic profile with the coordinate and sequential well-characterized plasma-membrane antigen expression. (b) Morphologic features and immunophenotypic expression pattern. (c) Representative images of the cell morphology using May Grunwald-Giemsa histochemical staining for DNA and RNA molecules. Scale bar: 10 μm.

Mentions: The first two cell models that we used were originally derived from patients with B-ALL: the RS4;11 and REH cell lines, which are both classified as the L2-blast (i.e., B-cell precursor leukemia) subtype4243444546. The third cell model was the MN60 cell line, which represents a more differentiated B-ALL cell type, as it is classified as the L3-blast (i.e., B-cell leukemia) subtype4748. To define these cell lines further, we initially carried out immunophenotypic and morphological characterization of the expression profiles of the sequential plasma-membrane antigens of these cell lines, as summarized in Fig. 1.


A reliable Raman-spectroscopy-based approach for diagnosis, classification and follow-up of B-cell acute lymphoblastic leukemia.

Managò S, Valente C, Mirabelli P, Circolo D, Basile F, Corda D, De Luca AC - Sci Rep (2016)

Differentiation scheme and morphology of the RS4;11, REH and MN60 B-leukemia cell lines.(a) Immunophenotypic profile with the coordinate and sequential well-characterized plasma-membrane antigen expression. (b) Morphologic features and immunophenotypic expression pattern. (c) Representative images of the cell morphology using May Grunwald-Giemsa histochemical staining for DNA and RNA molecules. Scale bar: 10 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4835730&req=5

f1: Differentiation scheme and morphology of the RS4;11, REH and MN60 B-leukemia cell lines.(a) Immunophenotypic profile with the coordinate and sequential well-characterized plasma-membrane antigen expression. (b) Morphologic features and immunophenotypic expression pattern. (c) Representative images of the cell morphology using May Grunwald-Giemsa histochemical staining for DNA and RNA molecules. Scale bar: 10 μm.
Mentions: The first two cell models that we used were originally derived from patients with B-ALL: the RS4;11 and REH cell lines, which are both classified as the L2-blast (i.e., B-cell precursor leukemia) subtype4243444546. The third cell model was the MN60 cell line, which represents a more differentiated B-ALL cell type, as it is classified as the L3-blast (i.e., B-cell leukemia) subtype4748. To define these cell lines further, we initially carried out immunophenotypic and morphological characterization of the expression profiles of the sequential plasma-membrane antigens of these cell lines, as summarized in Fig. 1.

Bottom Line: B-ALL diagnosis requires identification and classification of the leukemia cells.In combination with immunofluorescence and Western blotting, we show that these Raman markers reflect the relative changes in the potential biological markers from cell surface antigens, cytoplasmic proteins, and DNA content and correlate with the lymphoblastic B-cell maturation/differentiation stages.Our study demonstrates the potential of this technique for classification of B-leukemia cells into the different differentiation/maturation stages, as well as for the identification of key biochemical changes under chemotherapeutic treatments.

View Article: PubMed Central - PubMed

Affiliation: Institute of Protein Biochemistry, National Research Council, Via P. Castellino 111, 80131 Naples, Italy.

ABSTRACT
Acute lymphoblastic leukemia type B (B-ALL) is a neoplastic disorder that shows high mortality rates due to immature lymphocyte B-cell proliferation. B-ALL diagnosis requires identification and classification of the leukemia cells. Here, we demonstrate the use of Raman spectroscopy to discriminate normal lymphocytic B-cells from three different B-leukemia transformed cell lines (i.e., RS4;11, REH, MN60 cells) based on their biochemical features. In combination with immunofluorescence and Western blotting, we show that these Raman markers reflect the relative changes in the potential biological markers from cell surface antigens, cytoplasmic proteins, and DNA content and correlate with the lymphoblastic B-cell maturation/differentiation stages. Our study demonstrates the potential of this technique for classification of B-leukemia cells into the different differentiation/maturation stages, as well as for the identification of key biochemical changes under chemotherapeutic treatments. Finally, preliminary results from clinical samples indicate high consistency of, and potential applications for, this Raman spectroscopy approach.

No MeSH data available.


Related in: MedlinePlus